{"nctId":"NCT02717195","briefTitle":"Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia","startDateStruct":{"date":"2016-04"},"conditions":["Schizophrenia"],"count":1098,"armGroups":[{"label":"Prospective Confirmation (PC) Period","type":"EXPERIMENTAL","interventionNames":["Drug: Risperidone","Drug: Olanzapine"]},{"label":"Double-blind Treatment (DBT) Period, Lu AF35700 10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Lu AF35700"]},{"label":"DBT Period, Lu AF35700 20 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Lu AF35700"]},{"label":"DBT Period, Continued treatment from PC Period","type":"EXPERIMENTAL","interventionNames":["Drug: Risperidone","Drug: Olanzapine"]}],"interventions":[{"name":"Risperidone","otherNames":[]},{"name":"Olanzapine","otherNames":[]},{"name":"Lu AF35700","otherNames":[]},{"name":"Lu AF35700","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patient has schizophrenia, diagnosed according to DSM-5(TM) (Diagnostic and Statistical Manual of Mental Disorders) and confirmed by the Mini International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorders\n* The patient is either an inpatient at a psychiatric setting or outpatient consulting a psychiatrist.\n* Patients should be treated with adequate dose(s) and agent(s) of antipsychotic treatment for at least 2 weeks prior to Screening\n* The patient has failed to show an adequate response in the level of psychotic symptoms despite at least one documented treatment trial with an adequate dose of an antipsychotic agent prescribed for an adequate time (at least lasting for 6 weeks) during 2 years prior to Screening. The failure to respond to the current antipsychotic treatment trial may be considered a retrospective failed treatment, if the patient was treated for 6 weeks with adequate dose(s) and agent(s)\n* The patient has a PANSS total score of ≥80 and a score of ≥4 on at least 2 of the following PANSS items (at Screening and at the first visit of Period A)\n* The patient has a CGI-S score of ≥4 at Screening and at the first visit of Period A\n\nExclusion Criteria:\n\n* The patient has any current primary psychiatric disorder other than schizophrenia as assessed by the Mini International Neuropsychiatric Interview (MINI)\n* The patient is experiencing an acute exacerbation of his/her psychotic symptoms\n* The patient has not responded to treatment with clozapine\n\nOther protocol defined inclusion and exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Randomization to Week 10 in Positive and Negative Syndrome Scale (PANSS) Total Score","description":"PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.01","spread":"0.96"},{"groupId":"OG001","value":"-8.22","spread":"0.98"},{"groupId":"OG002","value":"-9.90","spread":"0.97"}]}]}]},{"type":"SECONDARY","title":"Change From Randomization to Week 10 in PSP Total Personal and Social Performance (PSP) Total Score","description":"PSP is a clinician-rated scale designed and validated to measure a patient's current level of social functioning. It consists of 4 items: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behaviours. Each items were assessed on a 6-point scale, from 1 (absent) to 6 (very severe). PSP score was calculated as sum of all the items on the scale and ranged from 4 to 100. A higher score represents more severe functional impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.90","spread":"0.96"},{"groupId":"OG001","value":"3.23","spread":"0.98"},{"groupId":"OG002","value":"3.94","spread":"0.98"}]}]}]},{"type":"SECONDARY","title":"Change From Randomization to Week 10 in Global Clinical Impression - Severity of Illness (CGI-S) Score","description":"CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). Higher scores indicate worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.59","spread":"0.06"},{"groupId":"OG001","value":"-0.54","spread":"0.06"},{"groupId":"OG002","value":"-0.57","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Response at Week 10, Defined as ≥20% Reduction in PANSS Total Score, PANSS (Positive and Negative Syndrome Scale) Total Score ≤70, CGI-S (Clinical Global Impression Scale - Severity of Illness) Score <4","description":"PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.\n\nThe Clinical Global Impression scale - severity of illness (CGI-S) is administered by the investigator. The patient is rated on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients). A reduction in scale indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Response at Week 10, Defined as ≥20% Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score From Randomization","description":"PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"77","spread":null}]}]}]},{"type":"SECONDARY","title":"Response at Week 10, Defined as ≥30% Reduction in PANSS Total Score From Randomization","description":"Positive and Negative Syndrome Scale (PANSS) total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"Response at Week 10, Defined as ≥40% Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score From Randomization","description":"PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Response at Week 10, Defined as ≥50% Reduction in Positive and Negative Syndrome Scale (PANSS) Total Score From Randomization","description":"PANSS total score administered by the investigator. It included 3 sub-scales with a total of 30 items that evaluated the Positive Symptoms subscale, the Negative Symptoms subscale, the General Psychopathology subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). PANSS total score was calculated as sum of all the items on the scale and ranged from 30 to 210. A higher score corresponded to a worse severity of schizophrenia. A reduction in score indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":708},"commonTop":["Somnolence","Headache","Akathisia","Weight increased"]}}}